{"schema_version":"1.0","type":"article","title":"減重針救不了肝硬化，諾和自己花47億美元補洞","url":"https://drugnews.com.tw/articles/2026-11-13-mash-cirrhosis-fgf21-novo-akero-glp1-fibrosis-gap.html","markdown_url":"https://drugnews.com.tw/articles/2026-11-13-mash-cirrhosis-fgf21-novo-akero-glp1-fibrosis-gap.md","lang":"zh-Hant","date":"2026-11-13","publish_at":"2026-11-13T08:00:00+08:00","updated_at":"2026-11-13","category":"醫學大會","topic":"醫學大會","tags":["脂肪肝","MASH","肝硬化","諾和諾德","AASLD 2026"],"summary":"AASLD 年會數據一致：減重針讓脂肪肝炎消退，纖維化改善幅度小得多。諾和以 47 億美元買 Akero、羅氏買 89bio，加碼條款都綁在肝硬化。Rezdiffra 單季 4.3 億美元，最多 53% 病人併用 GLP-1。","key_points":["AASLD 2026 上，survodutide 減重逾 15% 者脂肪肝炎消退 78.4%，纖維化改善 64.9%；saroglitazar 消退率達標、纖維化未達顯著。","諾和收購 Akero 的 6 美元 CVR、羅氏收購 89bio 的 CVR，都以 FGF21 藥在肝硬化取得核准或銷售為條件。","Rezdiffra 第三季銷售 4.313 億美元、年增 50%，真實世界資料顯示最多 53% 病人同時使用 GLP-1。"],"facts":[{"claim":"ESSENCE 72 週脂肪肝炎消退（semaglutide vs 安慰劑）","value":"63 vs 34","unit":"%","as_of":"2025-08-15","source":"HCPLive 2025-08-15"},{"claim":"ESSENCE 72 週纖維化改善（semaglutide vs 安慰劑）","value":"37 vs 22","unit":"%","as_of":"2025-08-15","source":"HCPLive 2025-08-15"},{"claim":"survodutide 減重≥15% 組脂肪肝炎消退","value":"78.4","unit":"%","as_of":"2026-11-07","source":"HCPLive 2026-11-07"},{"claim":"survodutide 減重≥15% 組纖維化改善","value":"64.9","unit":"%","as_of":"2026-11-07","source":"HCPLive 2026-11-07"},{"claim":"survodutide 減重<5% 組脂肪肝炎消退／纖維化改善","value":"36.8 / 47.4","unit":"%","as_of":"2026-11-07","source":"HCPLive 2026-11-07"},{"claim":"saroglitazar 4mg 脂肪肝炎消退 vs 安慰劑","value":"39.1 vs 13.7","unit":"%","as_of":"2026-11-08","source":"Tech Times 2026-11-08"},{"claim":"saroglitazar 4mg 纖維化改善 vs 安慰劑（不顯著）","value":"34.8 vs 24.6","unit":"%","as_of":"2026-11-08","source":"Tech Times 2026-11-08"},{"claim":"semaglutide 代償性肝硬化二期纖維化改善 vs 安慰劑","value":"11 vs 29","unit":"%","as_of":"2023-03-20","source":"HCPLive 2023-03-20"},{"claim":"諾和收購 Akero 現金總額","value":"47","unit":"億美元","as_of":"2025-10-09","source":"Novo Nordisk 2025-10-09"},{"claim":"Akero CVR（以肝硬化美國核准為條件）","value":"每股 6／約 5","unit":"美元／億美元","as_of":"2025-10-09","source":"Novo Nordisk 2025-10-09"},{"claim":"efruxifermin SYMMETRY 96 週肝硬化纖維化改善 vs 安慰劑","value":"29 vs 11","unit":"%","as_of":"2025-10-09","source":"Novo Nordisk 2025-10-09"},{"claim":"羅氏收購 89bio 總值上限","value":"35","unit":"億美元","as_of":"2025-09-18","source":"Fierce Biotech 2025-09-18"},{"claim":"Rezdiffra 2026 第三季淨銷售","value":"4.313","unit":"億美元","as_of":"2026-11-03","source":"SEC 2026-11-03"},{"claim":"Rezdiffra 銷售年增","value":"50","unit":"%","as_of":"2026-11-03","source":"SEC 2026-11-03"},{"claim":"Rezdiffra 用藥病人","value":"55850","unit":"人","as_of":"2026-09-30","source":"SEC 2026-11-03"},{"claim":"Rezdiffra 病人併用 GLP-1 比例上限","value":"53","unit":"%","as_of":"2026-11-05","source":"Madrigal 2026-11-05"},{"claim":"進展到肝硬化者肝臟相關死亡風險","value":"42","unit":"倍","as_of":"2026-11-05","source":"Madrigal 2026-11-05"},{"claim":"台灣成人代謝性脂肪肝盛行率","value":"33.3","unit":"%","as_of":"2026-06-09","source":"亞太新聞網 2026-06-09"},{"claim":"台灣脂肪肝人數","value":"約 700","unit":"萬人","as_of":"2026-06-09","source":"亞太新聞網 2026-06-09"},{"claim":"MASH 確診時已中重度纖維化比例","value":"40–52","unit":"%","as_of":"2026-06-09","source":"亞太新聞網 2026-06-09"},{"claim":"與脂肪肝相關的肝癌比例","value":"約 20","unit":"%","as_of":"2026-06-09","source":"亞太新聞網 2026-06-09"}],"sections":["01｜減重針退得掉發炎，退不掉疤痕","02｜諾和、羅氏的收購條款，把錢押在肝硬化那一關","03｜Rezdiffra 一季賣 4.3 億美元，靠的是跟減重針並用","04｜生意怎麼變：脂肪肝從減重門診，走進肝科的雙藥處方","05｜押錯的條件：GLP-1 長期數據逆轉，或肝硬化試驗集體翻車","06｜台灣：700 萬人有脂肪肝，先到的藥只管前半段","參考資料"],"references":[{"title":"Liver Drug Saroglitazar Nearly Triples Placebo's MASH Resolution Rate","source":"Tech Times","date":"2026-11-08","url":"https://www.techtimes.com/articles/330261/20261108/liver-drug-saroglitazar-nearly-triples-placebos-mash-resolution-rate-zydus-trial-shows.htm"},{"title":"Survodutide Improves MASH Liver Endpoints Across Weight Loss Categories","source":"HCPLive","date":"2026-11-07","url":"https://www.hcplive.com/view/survodutide-improves-mash-liver-endpoints-across-weight-loss-categories"},{"title":"GLP-1s Lower MASH Activity but Not Fibrosis: Winston Dunn","source":"AJMC","date":"2026-11-07","url":"https://www.ajmc.com/view/glp-1s-lower-mash-activity-but-not-fibrosis-winston-dunn-md-faasld"},{"title":"Madrigal Announces New Real-World Data at AASLD 2026","source":"Madrigal Pharmaceuticals（GlobeNewswire","date":"2026-11-05","url":"https://www.globenewswire.com/news-release/2026/11/05/3396655/0/en/madrigal-announces-new-real-world-data-at-aasld-2026-demonstrating-improvements-in-liver-stiffness-and-cardiometabolic-health-markers-with-rezdiffra.html"},{"title":"Madrigal Third Quarter 2026 Financial Results（Form 8-K Ex.99.1","source":"SEC","date":"2026-11-03","url":"https://www.sec.gov/Archives/edgar/data/0001157601/000162828026069093/exhibit991-93026earningspr.htm"},{"title":"GSK showcases progress in liver portfolio at AASLD 2026","source":"GSK","date":"2026-11-05","url":"https://www.gsk.com/en-gb/media/press-releases/gsk-showcases-progress-in-liver-portfolio-at-aasld-2026/"},{"title":"Novo to present new liver data across Wegovy 2.4 mg and investigational efruxifermin at AASLD 2026","source":"Novo Nordisk（PR Newswire","date":"2026-10-28","url":"https://www.prnewswire.com/news-releases/novo-to-present-new-liver-data-across-wegovy-2-4-mg-and-investigational-efruxifermin-at-the-liver-meeting-aasld-2026--302922177.html"},{"title":"Novo Nordisk Financial Report Q3 2026（Form 6-K","source":"SEC","date":"2026-11-04","url":"https://www.sec.gov/Archives/edgar/data/0000353278/000162828026069805/caq32026.htm"},{"title":"Novo Nordisk to acquire Akero Therapeutics","source":"Novo Nordisk","date":"2025-10-09","url":"https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916433"},{"title":"Roche becomes MASH player via $3.5B deal for 89bio","source":"Fierce Biotech","date":"2025-09-18","url":"https://www.fiercebiotech.com/biotech/roche-becomes-mash-player-35b-deal-89bio-and-its-phase-3-drug"},{"title":"FDA Approves Semaglutide (Wegovy) for Noncirrhotic MASH","source":"HCPLive","date":"2025-08-15","url":"https://www.hcplive.com/view/fda-approves-semaglutide-wegovy-injection-2-4-mg-for-noncirrhotic-mash"},{"title":"Semaglutide Well Tolerated, Shows Lack of Improvement in Liver Fibrosis","source":"HCPLive","date":"2023-03-20","url":"https://www.hcplive.com/view/semaglutide-well-tolerated-shows-lack-improvement-liver-fibrosis"},{"title":"Intercept Receives Complete Response Letter for Obeticholic Acid in NASH Fibrosis（Form 8-K Ex.99.1","source":"SEC","date":"2023-06-22","url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923073909/tm2319514d1_ex99-1.htm"},{"title":"每3人就1人有脂肪肝 WHO示警成全球健康挑戰","source":"亞太新聞網（蕃新聞","date":"2026-06-09","url":"https://n.yam.com/Article/20260609146222"},{"title":"114年死因統計結果","source":"衛生福利部","date":"2026-06-22","url":"https://mohw.gov.tw/cp-16-86970-1.html"}],"images":[{"alt":"圖1｜三個藥、同一種形狀：發炎消退好拿，纖維化改善難拿","url":"https://drugnews.com.tw/assets/articles/mash-cirrhosis-fgf21-novo-akero-glp1-fibrosis-gap/figure-01.png"},{"alt":"圖2｜四家大藥廠的肝硬化押注","url":"https://drugnews.com.tw/assets/articles/mash-cirrhosis-fgf21-novo-akero-glp1-fibrosis-gap/figure-02.png"},{"alt":"圖3｜脂肪肝的雙藥時代：減重針管前段，肝臟藥搶後段","url":"https://drugnews.com.tw/assets/articles/mash-cirrhosis-fgf21-novo-akero-glp1-fibrosis-gap/figure-03.png"},{"alt":"圖4｜台灣脂肪肝：病人多、來得晚","url":"https://drugnews.com.tw/assets/articles/mash-cirrhosis-fgf21-novo-akero-glp1-fibrosis-gap/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/mash-cirrhosis-fgf21-novo-akero-glp1-fibrosis-gap/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-11-13）。減重針救不了肝硬化，諾和自己花47億美元補洞。https://drugnews.com.tw/articles/2026-11-13-mash-cirrhosis-fgf21-novo-akero-glp1-fibrosis-gap.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/","faq":[{"q":"「AASLD 2026 上，survodutide 減重逾 15% 者脂肪肝炎消退 78.4%，纖維化改善 64.9%」有哪些關鍵變化？","a":"AASLD 2026 上，survodutide 減重逾 15% 者脂肪肝炎消退 78.4%，纖維化改善 64.9%；saroglitazar 消退率達標、纖維化未達顯著。"},{"q":"「諾和收購 Akero 的 6 美元 CVR、羅氏收購 89bio 的 CVR，都以 FGF21 藥在肝硬化取得核准或銷售為條件」有哪些關鍵變化？","a":"諾和收購 Akero 的 6 美元 CVR、羅氏收購 89bio 的 CVR，都以 FGF21 藥在肝硬化取得核准或銷售為條件。"},{"q":"「Rezdiffra 第三季銷售 4.313 億美元、年增 50%，真實世界資料顯示最多 53% 病人同時使用 GLP-1」有哪些關鍵變化？","a":"Rezdiffra 第三季銷售 4.313 億美元、年增 50%，真實世界資料顯示最多 53% 病人同時使用 GLP-1。"}]}